Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13058476 | 0.90 | SMN1; SMN2 (0.36) | MAPTKDM4EGAA | |
| SCHEMBL13058480 | 0.88 | RAB9A (0.38) | MAPTKDM4EGAA | |
| SCHEMBL13058493 | 0.88 | KDM4E (0.34) | MAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL13058543 | 0.86 | FBP1 (0.31) | — | |
| SCHEMBL13058478 | 0.86 | ALDH1A1 (0.39) | MAPTKDM4EL3MBTL1 | |
| SCHEMBL13058548 | 0.86 | NPC1 (0.40) | MAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL13058546 | 0.84 | — | — | |
| SCHEMBL13058498 | 0.83 | ALDH1A1 (0.39) | MAPTKDM4EL3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL13058527 | 0.82 | RAB9A (0.36) | MAPTGAA | |
| SCHEMBL10237965 | 0.81 | RARA (0.31) | MAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188294-B1 | TRICYCLIC BRIDGED CYCLOPENTANEDIONE DERIVATIVES AS HERBICIDES | SYNGENTA LTD (GB) | 2015-03-18 | — | — | EP | disclosed |
| US-8530667-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530667-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20100298140-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298140-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2009030450-A2 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298140-A1 | NOVEL HERBICIDES | DDT, CYP1B1, CYP1A1 | MAPT 3984/4885KDM4E 1070/4885GAA 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.